SEC Form 4 · accession 0001209191-18-061329
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Nov 27, 2018
Accepted (ET)
Dec 6, 2018 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 27, 2018 | G | 40,000 | $0.00 | D | 2,689,304 | I | See footnote |
| Common StockF4,F2 | Dec 3, 2018 | S | 17,933 | $18.4171 | D | 2,671,371 | I | See footnote |
| Common StockF5,F2 | Dec 3, 2018 | S | 400 | $19.16 | D | 2,670,971 | I | See footnote |
| Common Stock | holding | — | — | — | 12,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund.
- F2The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F3The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.05 to $18.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.